NEUCA Valuation
Is NEU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NEU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NEU (PLN919) is trading below our estimate of fair value (PLN1480.64)
Significantly Below Fair Value: NEU is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NEU?
Other financial metrics that can be useful for relative valuation.
| What is NEU's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | zł4.11b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | 13.3x |
| PEG Ratio | 1.4x |
Price to Earnings Ratio vs Peers
How does NEU's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 33.6x | ||
VOX Voxel | 12x | 4.4% | zł974.6m |
ENE Centrum Medyczne ENEL-MED | 73x | n/a | zł503.4m |
EMC EMC Instytut Medyczny | 38.7x | n/a | zł462.1m |
600713 NanJing Pharmaceutical | 10.8x | n/a | CN¥6.4b |
NEU NEUCA | 28.1x | 20.0% | zł4.1b |
Price-To-Earnings vs Peers: NEU is good value based on its Price-To-Earnings Ratio (28.1x) compared to the peer average (33.6x).
Price to Earnings Ratio vs Industry
How does NEU's PE Ratio compare vs other companies in the European Healthcare Industry?
Price-To-Earnings vs Industry: NEU is expensive based on its Price-To-Earnings Ratio (28.1x) compared to the European Healthcare industry average (18.3x).
Price to Earnings Ratio vs Fair Ratio
What is NEU's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 28.1x |
| Fair PE Ratio | 21.2x |
Price-To-Earnings vs Fair Ratio: NEU is expensive based on its Price-To-Earnings Ratio (28.1x) compared to the estimated Fair Price-To-Earnings Ratio (21.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | zł919.00 | zł974.67 +6.1% | 9.4% | zł1,066.00 | zł850.00 | n/a | 3 |
| Apr ’25 | zł892.00 | zł974.67 +9.3% | 9.4% | zł1,066.00 | zł850.00 | n/a | 3 |
| Mar ’25 | zł889.00 | zł974.67 +9.6% | 9.4% | zł1,066.00 | zł850.00 | n/a | 3 |
| Feb ’25 | zł896.00 | zł977.67 +9.1% | 9.6% | zł1,075.00 | zł850.00 | n/a | 3 |
| Jan ’25 | zł925.00 | zł977.67 +5.7% | 9.6% | zł1,075.00 | zł850.00 | n/a | 3 |
| Dec ’24 | zł832.00 | zł926.67 +11.4% | 11.3% | zł1,075.00 | zł850.00 | n/a | 3 |
| Nov ’24 | zł760.00 | zł898.33 +18.2% | 7.2% | zł990.00 | zł850.00 | n/a | 3 |
| Oct ’24 | zł666.00 | zł898.33 +34.9% | 7.2% | zł990.00 | zł850.00 | n/a | 3 |
| Sep ’24 | zł735.00 | zł898.33 +22.2% | 7.2% | zł990.00 | zł850.00 | n/a | 3 |
| Aug ’24 | zł770.00 | zł865.33 +12.4% | 11.1% | zł990.00 | zł756.00 | n/a | 3 |
| Jul ’24 | zł763.00 | zł802.00 +5.1% | 17.3% | zł990.00 | zł660.00 | n/a | 3 |
| Jun ’24 | zł722.00 | zł802.00 +11.1% | 17.3% | zł990.00 | zł660.00 | n/a | 3 |
| May ’24 | zł675.00 | zł706.00 +4.6% | 5.6% | zł756.00 | zł660.00 | zł912.00 | 3 |
| Apr ’24 | zł613.00 | zł667.47 +8.9% | 3.8% | zł702.00 | zł640.40 | zł892.00 | 3 |
| Mar ’24 | zł597.00 | zł657.47 +10.1% | 4.8% | zł702.00 | zł630.00 | zł889.00 | 3 |
| Feb ’24 | zł617.00 | zł657.47 +6.6% | 4.8% | zł702.00 | zł630.00 | zł896.00 | 3 |
| Jan ’24 | zł650.00 | zł630.80 -3.0% | 9.9% | zł702.00 | zł550.00 | zł925.00 | 3 |
| Dec ’23 | zł628.00 | zł630.80 +0.4% | 9.9% | zł702.00 | zł550.00 | zł832.00 | 3 |
| Nov ’23 | zł610.00 | zł720.80 +18.2% | 17.8% | zł902.00 | zł620.00 | zł760.00 | 3 |
| Oct ’23 | zł655.00 | zł815.03 +24.4% | 17.0% | zł923.10 | zł620.00 | zł666.00 | 3 |
| Sep ’23 | zł715.00 | zł875.03 +22.4% | 6.1% | zł923.10 | zł800.00 | zł735.00 | 3 |
| Aug ’23 | zł780.00 | zł875.03 +12.2% | 6.1% | zł923.10 | zł800.00 | zł770.00 | 3 |
| Jul ’23 | zł784.00 | zł917.37 +17.0% | 1.2% | zł927.00 | zł902.00 | zł763.00 | 3 |
| Jun ’23 | zł768.00 | zł888.37 +15.7% | 5.8% | zł927.00 | zł815.00 | zł722.00 | 3 |
| May ’23 | zł750.00 | zł888.37 +18.4% | 5.8% | zł927.00 | zł815.00 | zł675.00 | 3 |
Analyst Forecast: Target price is less than 20% higher than the current share price.